Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer
JWD Hearn, W Xie, M Nakabayashi, N Almassi… - JAMA …, 2018 - jamanetwork.com
Importance The variantHSD3B1 (1245C) allele enhances dihydrotestosterone synthesis and
predicts resistance to androgen-deprivation therapy (ADT) for biochemically recurrent
prostate cancer after prostatectomy and for metastatic disease. Whether this is true after
radiotherapy is unknown. Objective To determine whether theHSD3B1 (1245C) allele
predicts worse clinical outcomes from ADT for biochemical recurrence after radiotherapy.
Design, Setting, and Participants The Prostate Clinical Research Information System at …
predicts resistance to androgen-deprivation therapy (ADT) for biochemically recurrent
prostate cancer after prostatectomy and for metastatic disease. Whether this is true after
radiotherapy is unknown. Objective To determine whether theHSD3B1 (1245C) allele
predicts worse clinical outcomes from ADT for biochemical recurrence after radiotherapy.
Design, Setting, and Participants The Prostate Clinical Research Information System at …